Add-on durvalumab (Imfinzi) reduced the number of early high-risk disease recurrences within the first year in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results